Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bonazzi, Vanessa F ^a   Nancarrow, Derek J ^a   Stark, Mitchell S ^a   Moser, Ralf J ^a   Boyle, Glen M ^a   Aoude, Lauren G ^a   Schmidt, Christopher ^a   Hayward, Nicholas K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; THROMBOSPONDIN 1; UBIQUITIN THIOLESTERASE; ALPHA 2(I) COLLAGEN; COLLAGEN TYPE 1; TNFRSF10D PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; UCHL1 PROTEIN, HUMAN;

ARTICLE; COL1A2 GENE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; PROMOTER REGION; PROTEIN EXPRESSION; THROMBOSPONDIN 1 GENE; TNFRSF10D GENE; TUMOR SUPPRESSOR GENE; UBIQUITIN COOH TERMINAL ESTERASE L1 GENE; ANIMAL; DNA MICROARRAY; GENETICS; METABOLISM; NEWBORN; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLLAGEN TYPE I; CPG ISLANDS; DNA METHYLATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; INFANT, NEWBORN; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SKIN NEOPLASMS; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR DECOY RECEPTORS; UBIQUITIN THIOLESTERASE;

EID: 80054784994     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026121     Document Type: Article

References (63)

1. Esteller M, (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
2. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128: 683-692.
3. Baylin SB, (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): S4-11.
4. Takai D, Jones PA, (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 99: 3740-3745.
5. Bauer AP, Leikam D, Krinner S, Notka F, Ludwig C, et al. (2010) The impact of intragenic CpG content on gene expression. Nucleic Acids Res 38: 3891-3908.
6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147.
7. Stark M, Hayward N, (2007) Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 67: 2632-2642.
8. Richards HW, Medrano EE, (2009) Epigenetic marks in melanoma. Pigment Cell Melanoma Res 22: 14-29.
9. Rothhammer T, Bosserhoff AK, (2007) Epigenetic events in malignant melanoma. Pigment Cell Res 20: 92-111.
10. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, et al. (2010) Aberrant DNA methylation in malignant melanoma. Melanoma Res 20: 253-265.
11. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, et al. (2005) Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26: 1856-1867.
12. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66: 11187-11193.
13. van der Velden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, et al. (2003) Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer 106: 472-479.
14. Bonazzi VF, Irwin D, Hayward NK, (2009) Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosomes Cancer 48: 10-21.
15. Coolen MW, Statham AL, Gardiner-Garden M, Clark SJ, (2007) Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 35: e119.
16. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, et al. (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 102: 15785-15790.
17. Weisenberger DJdBD, Pan F, Berman BP, Laird PW, (2008) Comprehensive DNA methylation analysis on the Illumina Infinium assay platform. In: Illumina I, editors. Available: http://www.illumina.com/Documents/products/appnotes/appnote_infinium_methylation.pdf San Diego: Technical report. Accessed 2011 Sep.
18. Johansson P, Pavey S, Hayward N, (2007) Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res 20: 216-221.
19. Packer LM, Pavey SJ, Boyle GM, Stark MS, Ayub AL, et al. (2007) Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. Int J Cancer 121: 784-790.
20. Ehrich M, Zoll S, Sur S, van den Boom D, (2007) A new method for accurate assessment of DNA quality after bisulfite treatment. Nucleic Acids Res 35: e29.
21. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, et al. (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res.
22. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, et al. (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63: 1114-1121.
23. Liu S, Ren S, Howell P, Fodstad O, Riker AI, (2008) Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 21: 545-558.
24. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, et al. (2009) Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS ONE 4: e4563.
25. Ghosh AK, Bhattacharyya S, Varga J, (2004) The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279: 47455-47463.
26. Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, et al. (2008) Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol 10: 981-994.
27. Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, et al. (2005) Identification and investigation of methylated genes in hepatoma. Eur J Cancer 41: 1185-1194.
28. Sengupta PK, Smith EM, Kim K, Murnane MJ, Smith BD, (2003) DNA hypermethylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers. Cancer Res 63: 1789-1797.
29. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD, (2009) Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 9: 182-194.
30. Yang Q, Tian Y, Ostler KR, Chlenski A, Guerrero LJ, et al. (2010) Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer 10: 286.
31. Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, et al. (2003) Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 63: 6299-6310.
32. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, et al. (2006) CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45: 781-789.
33. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH, (2004) Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 84: 884-893.
34. Rojas A, Meherem S, Kim YH, Washington MK, Willis JE, et al. (2008) The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer 123: 14-21.
35. Guo W, Dong Z, He M, Guo Y, Guo J, et al. (2010) Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol 2010: 721485.
36. Kim JH, Jung EJ, Lee HS, Kim MA, Kim WH, (2009) Comparative analysis of DNA methylation between primary and metastatic gastric carcinoma. Oncol Rep 21: 1251-1259.
37. Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, et al. (2003) Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 64: 423-429.
38. Gonzalez-Gomez P, Bello MJ, Alonso ME, Aminoso C, Lopez-Marin I, et al. (2004) Promoter methylation status of multiple genes in brain metastases of solid tumors. Int J Mol Med 13: 93-98.
39. Guerrero D, Guarch R, Ojer A, Casas JM, Ropero S, et al. (2008) Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU Int 102: 747-755.
40. Sheikh MS, Fornace AJ Jr, (2000) Death and decoy receptors and p53-mediated apoptosis. Leukemia 14: 1509-1513.
41. Liu X, Yue P, Khuri FR, Sun SY, (2005) Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 65: 9169-9175.
42. Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, et al. (2004) Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109: 786-792.
43. van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, et al. (2002) Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62: 2157-2161.
44. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, et al. (2007) Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 13: 3191-3197.
45. Day IN, Thompson RJ, (2010) UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurobiol 90: 327-362.
46. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr, (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111: 209-218.
47. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, et al. (2008) The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 123: 753-759.
48. Li L, Tao Q, Jin H, van Hasselt A, Poon FF, et al. (2010) The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 16: 2949-2958.
49. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, et al. (2008) Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 48: 508-518.
50. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, et al. (2005) PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65: 4963-4968.
51. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, et al. (2006) PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 66: 3921-3927.
52. Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, et al. (2008) CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol 180: 343-351.
53. Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, et al. (2005) Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 7: 748-760.
54. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, et al. (2006) Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 119: 1338-1344.
55. Mizukami H, Shirahata A, Goto T, Sakata M, Saito M, et al. (2008) PGP9.5 methylation as a marker for metastatic colorectal cancer. Anticancer Res 28: 2697-2700.
56. Tezel E, Hibi K, Nagasaka T, Nakao A, (2000) PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 6: 4764-4767.
57. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, et al. (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64: 5270-5282.
58. Box NF, Terzian T, (2008) The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 21: 525-533.
59. Loss LA, Sadanandam A, Durinck S, Nautiyal S, Flaucher D, et al. (2010) Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics 11: 305.
60. Sjahputera O, Keller JM, Davis JW, Taylor KH, Rahmatpanah F, et al. (2007) Relational analysis of CpG islands methylation and gene expression in human lymphomas using possibilistic C-means clustering and modified cluster fuzzy density. IEEE/ACM Trans Comput Biol Bioinform 4: 176-189.
61. Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, et al. (1997) CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57: 4868-4875.
62. Leonard JH, Marks LH, Chen W, Cook AL, Boyle GM, et al. (2003) Screening of human primary melanocytes of defined melanocortin-1 receptor genotype: pigmentation marker, ultrastructural and UV-survival studies. Pigment Cell Res 16: 198-207.
63. Pavey S, Johansson P, Packer L, Taylor J, Stark M, et al. (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 4060-4067.